Apixaban Teva
On the Bulgarian pack: Апиксабан Тева 5 mg филмирани таблетки
5 mg film-coated tablets 200x1 · film - coated tablets
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Apixaban
- Used in
- Blood, clotting and anaemia
- Made by
- Teva Pharma EAD
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Apixaban is a selective inhibitor of FXa.
It does not require antithrombin III for antithrombotic activity.
Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
Apixaban is eliminated in both urine and feces.
Food does not affect the bioavailability of apixaban.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-03
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.
- ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] Active pathological bleeding (4) Severe hypersensitivity to ELIQUIS (4)
Most common adverse reactions (>1%) are related to bleeding.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva Pharma EAD · Bulgaria |
|---|---|
| Active substance | Apixaban |
| Used in | Blood, clotting and anaemia |
| Strength | 5 mg film-coated tablets 200x1 |
| Form | film - coated tablets |
| Pack sizes | 200 |
| Classification | B01AF02 · Blood, clotting and anaemia |
| Name in the register | Апиксабан Тева 5 mg филмирани таблетки |
| Reg. no. | 20210110 |
Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician
Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Other strengths and forms
23 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- film - coated tablets23 products
- 2,5 mg film-coated tablets 10x1
- 2,5 mg film-coated tablets 14x1
- 2,5 mg film-coated tablets 20x1
- 2,5 mg film-coated tablets 30x1
- 2,5 mg film-coated tablets 60x1
- 2,5 mg film-coated tablets 120x1
- 2,5 mg
- 2,5 mg film-coated tablets 200x1
- 2,5 mg film-coated tablets 168x1
- 2,5 mg film-coated tablets 100x1
- 2,5 mg film-coated tablets 56x1
- 5 mg film-coated tablets 200x1
- 5 mg film-coated tablets 10x1
- 5 mg film-coated tablets 14x1
- 5 mg film-coated tablets 20x1
- 5 mg film-coated tablets 28x1
- 5 mg film-coated tablets 56x1
- 5 mg film-coated tablets 100x1
- 5 mg
- 5 mg film-coated tablets 168x1
- 5 mg film-coated tablets 120x1
- 5 mg film-coated tablets 60x1
- 5 mg film-coated tablets 30x1
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.